Category Archives: Biotechnology

The 56 rating InvestorsObserver gives to Oncolytics Biotech, Inc. (ONCY) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 64 percent of stocks in the Biotechnology industry, ONCYs 56 overall rating means the stock scores better than 56 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Oncolytics Biotech, Inc. (ONCY) stock is up 1.91% while the S&P 500 is lower by -0.6% as of 3:00 PM on Wednesday, Oct 14. ONCY is higher by $0.04 from the previous closing price of $2.08 on volume of 475,049 shares. Over the past year the S&P 500 is higher by 16.53% while ONCY is higher by 341.67%. ONCY lost -$0.78 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

Read the original:
Where Does Oncolytics Biotech, Inc. (ONCY) Stock Fall in the Biotechnology Field? - InvestorsObserver

The 52 rating InvestorsObserver gives to Nantkwest Inc (NK) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 55 percent of stocks in the Biotechnology industry, NKs 52 overall rating means the stock scores better than 52 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Nantkwest Inc (NK) stock is trading at $9.27 as of 2:09 PM on Wednesday, Oct 14, a drop of -$0.17, or -1.8% from the previous closing price of $9.44. The stock has traded between $9.13 and $9.94 so far today. Volume today is 859,449 compared to average volume of 1,111,019.

Click Here to get the full Stock Score Report on Nantkwest Inc (NK) Stock.

See the original post here:
Is Nantkwest Inc (NK) The Right Choice in Biotechnology? - InvestorsObserver

SAN DIEGO--(BUSINESS WIRE)--Allele Biotechnology and Pharmaceuticals, Inc. (Allele), a San Diego-based company focused on developing and adapting cutting edge technology for clinical and therapeutic use, filed two patent infringement lawsuits today one in New York against Regeneron Pharmaceuticals and the other in California against Pfizer and BioNTech. Both complaints address the infringement of Alleles patented mNeonGreen technology, an important reagent used in the development of therapeutics for COVID-19.

Alleles mNeonGreen protein is considered the worlds brightest monomeric fluorescent protein, and the technology behind that protein was patented in 2019. Prominent scientific journals have touted the use of mNeonGreen as the gold standard for use in assays testing neutralizing antibody and vaccine candidates. Regeneron, Pfizer, and BioNTech used mNeonGreen commercially without authorization from Allele.

I am pleased that mNeonGreen has played a pivotal role in the fight against COVID-19. In no way does Allele want to prohibit, or slow down development of vaccines or therapeutics discovered using this technology, says Dr. Jiwu Wang, Founder and CEO of Allele. Our goal is to have these companies recognize, as many others have before them, the hard work that went in to developing this technology and to respect our intellectual property.

Hundreds of organizations and universities have active licenses to use Alleles mNeonGreen technology. According to the complaint, Allele reached out to Regeneron on multiple occasions to negotiate a license on reasonable terms, but all of its requests went unanswered. In fact, no defendant sought any permission in advance of using mNeonGreen to obtain breakthrough successes in developing and testing their vaccines.

The purpose of these lawsuits is to maintain Allele's patent rights and to ensure that an agreement can be put in place to protect the rights of current and future licensees, says Dan Catron, Executive Director, Licensing and Business Development for Allele.

Perkins Coie LLP is representing Allele in the New York filing. Troutman Pepper Hamilton Sanders LLP is representing Allele in the California lawsuits.

About Allele Biotechnology and Pharmaceuticals Inc.

Established in 1999, Allele Biotechnology has focused on developing and adapting cutting edge technology for clinical and therapeutic use. Allele has worked on biological advancements that have been at the forefront of molecular biology research, including RNA interference, fluorescent proteins, induced Pluripotent Stem Cells (iPSCs), and camelid-derived, single-domain nanoantibodies. With the advent of the global pandemic, Allele initiated the development of a series of llama nanoantibodies against SARS-CoV-2, the virus responsible for COVID-19. To learn more, go to https://www.allelebiotech.com.

Go here to see the original:
Allele Biotechnology and Pharmaceuticals Files Two Lawsuits for Patent Infringement for the Unauthorized Use of mNeonGreen in Development and Testing...

A rating of 85 puts SpringWorks Therapeutics Inc (SWTX) near the top of the Biotechnology industry according to InvestorsObserver. SpringWorks Therapeutics Inc's score of 85 means it scores higher than 85% of stocks in the industry. SpringWorks Therapeutics Inc also received an overall rating of 69, putting it above 69% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

SpringWorks Therapeutics Inc (SWTX) stock is trading at $55.01 as of 11:44 AM on Friday, Oct 9, an increase of $3.03, or 5.83% from the previous closing price of $51.98. The stock has traded between $52.79 and $56.45 so far today. Volume today is 339,767 compared to average volume of 364,745.

Click Here to get the full Stock Score Report on SpringWorks Therapeutics Inc (SWTX) Stock.

Originally posted here:
Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field? - InvestorsObserver

Abeona Therapeutics Inc (ABEO) is near the middle in its industry group according to InvestorsObserver. ABEO gets an overall rating of 42. That means it scores higher than 42 percent of stocks. Abeona Therapeutics Inc gets a 34 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 42 would rank higher than 42 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Abeona Therapeutics Inc (ABEO) stock is trading at $1.49 as of 11:29 AM on Friday, Oct 9, a rise of $0.11, or 7.61% from the previous closing price of $1.38. The stock has traded between $1.40 and $1.58 so far today. Volume today is 2,298,910 compared to average volume of 2,423,598.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

More:
Where Does Abeona Therapeutics Inc (ABEO) Stock Fall in the Biotechnology Field? - InvestorsObserver

A rating of 78 puts Rapt Therapeutics Inc (RAPT) near the top of the Biotechnology industry according to InvestorsObserver. Rapt Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Rapt Therapeutics Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 23 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Rapt Therapeutics Inc (RAPT) stock is trading at $36.59 as of 1:24 PM on Friday, Oct 9, an increase of $2.76, or 8.16% from the previous closing price of $33.83. The stock has traded between $34.01 and $37.06 so far today. Volume today is light. So far 102,755 shares have traded compared to average volume of 257,588 shares.

Click Here to get the full Stock Score Report on Rapt Therapeutics Inc (RAPT) Stock.

View original post here:
Should You Buy Rapt Therapeutics Inc (RAPT) in Biotechnology Industry? - InvestorsObserver